Plain-English translation of NCT06770270 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a medication that helps your immune system fight cancer, works better when combined with standard radiation therapy and chemotherapy for advanced rectal cancer. Right now, the standard treatment (radiation plus chemotherapy alone) only helps about 20-30% of patients achieve complete remission. Researchers hope that adding this immune-boosting medication to the standard treatment will help more patients respond better and reduce the chance of cancer returning.
Most rectal cancer patients don't respond well enough to radiation and chemotherapy alone, and many experience cancer recurrence or spread. This medication has shown promise in other cancers by helping the immune system recognize and attack cancer cells, so researchers want to see if it can improve results when used alongside standard treatment.
You likely qualify if…
You likely don't qualify if…
You would receive the new immune-boosting medication () alongside standard radiation therapy and chemotherapy as preparation for surgery. This treatment happens before your surgical procedure to try to shrink the tumor and improve surgical outcomes. You would need to attend regular medical visits for treatment sessions, blood tests, and imaging scans to monitor how well the treatment is working and check for any side effects.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China